These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19217354)

  • 1. Dosimetric outcomes in prostate brachytherapy: is downsizing the prostate with androgen deprivation necessary?
    Gibbons EP; Jacobs BL; Smith RP; Beriwal S; Krishna K; Benoit RM
    Brachytherapy; 2009; 8(3):304-8. PubMed ID: 19217354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose-rate brachytherapy for large prostate volumes (> or =50cc)-Uncompromised dosimetric coverage and acceptable toxicity.
    Monroe AT; Faricy PO; Jennings SB; Biggers RD; Gibbs GL; Peddada AV
    Brachytherapy; 2008; 7(1):7-11. PubMed ID: 18299109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI-based preplanning in low-dose-rate prostate brachytherapy.
    Tanaka O; Hayashi S; Matsuo M; Nakano M; Kubota Y; Maeda S; Ohtakara K; Deguchi T; Hoshi H
    Radiother Oncol; 2008 Jul; 88(1):115-20. PubMed ID: 17933407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
    Potters L; Calugaru E; Jassal A; Presser J
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
    Stone NN; Marshall DT; Stone JJ; Cesaretti JA; Stock RG
    J Urol; 2010 Feb; 183(2):634-9. PubMed ID: 20018308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
    Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP
    BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
    D'Souza WD; Thames HD; Kuban DA
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
    Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
    Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume.
    Stone NN; Stock RG
    J Urol; 2007 Mar; 177(3):925-8. PubMed ID: 17296377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
    Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
    Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
    Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of MRI-based postimplant dosimetric assessment in prostate brachytherapy using contrast-enhanced T1-weighted images.
    Ohashi T; Momma T; Yamashita S; Nagatsuma K; Kanai K; Kitagawa K; Takahashi S; Hanada T; Yorozu A; Shigematsu N
    Brachytherapy; 2012; 11(6):468-75. PubMed ID: 22330102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume.
    Petit JH; Gluck C; Kiger WS; Laury Henry D; Karasiewicz C; Talcott JA; Berg S; Holupka EJ; Kaplan ID
    Brachytherapy; 2007; 6(4):267-71. PubMed ID: 17959423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer.
    Corner C; Rojas AM; Bryant L; Ostler P; Hoskin P
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):441-6. PubMed ID: 18249501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ; Chen J; Stenger A; Matzkin H
    Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Greater postimplant swelling in small-volume prostate glands: implications for dosimetry, treatment planning, and operating room technique.
    Chung E; Stenmark MH; Evans C; Narayana V; McLaughlin PW
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1944-8. PubMed ID: 21640498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.